Pharmaceutical Companies

The Colorado representative's comments were "not factual and misleading," a women's policy expert said.

The pharmaceutical giant posted income of over $100 billion in 2022, the majority coming from Covid products, but it expects to lose out as the pandemic wanes.

Lawmakers from both the U.S. and U.K. have written to the two pharmaceutical companies to express concerns over plans to raise the price of a dose to $110-$130.

Governments in rich countries, such as the U.S. and U.K., knowingly allowed low- and middle-income countries to go unvaccinated.

Attorney General Bob Ferguson has taken McKesson Corp., Cardinal Health Inc. and Amerisource Bergen Corp. to court.

Over 3,300 lawsuits have been filed across the U.S. over an opioid epidemic that led to nearly 500,000 overdose deaths between 1999 and 2019.

"It was important to the board that the market share of abuse-deterrent opioids grew because we believed and were told repeatedly by management that abuse-deterrent opioids saved lives," Mortimer D.A. Sackler said.

"We need a release that's sufficient to get our goals accomplished," Sackler said responding to the U.S. bankruptcy trustee's lawyer.

The recall was issued after low levels of benzene, a chemical that can cause cancer, were detected in samples of sunscreen products from Neutrogena and Aveeno.

Organic and non-GMO ingredients should be used whenever possible, and should be sourced responsibly and ethically with stringent policies in place.

The West Virginia city of Huntington and surrounding Cabell County sued the nation's three largest opioid distributors after more than 700 people died over five years in a county with a population of less than 100,000.

Millions of Americans have already received at least one dose of the COVID-19 vaccines, but many people wonder if pharmaceutical companies will be liable in the event of a vaccine-related injury.

Trump's numerous vows to have a COVID-19 vaccine before Election Day have been criticized by physicians who said the unfulfilled campaign promises must stop.

Republicans should unify behind one approach with the potential to be decisive for anyone who isn't a hard partisan. That approach is to promote the right to know health care prices up front—health care price transparency.

"The vast costs associated with health care represent one of the most important and contentious issues facing Americans today," said researcher Joseph Dieleman.

For starters, taking the company private could take more than $55 billion in debt, a tough move to finance amid slumping stocks.

One key factor is that people only take antibiotics for a short period of time, just until an infection clears.

What will it take for pharmaceutical companies to create a viable strep vaccine?

Azar will be replacing Tom Price, the former HHS secretary who resigned amid a private plane scandal in September.

Democracy Forward is suing for details about a former pharmaceutical lobbyist's role in drug regulation.

The maker of Botox has been accused of unethical practices—but those accusations are also raising suspicions.

The former supervisor of now-defunct New England Compounding Center could receive a life sentence for second-degree murder in case linked to the deaths of more than 70 people.

We need to flat-out socialize the development of new antibiotics, and increasingly regulate the use of existing ones.

Pharmacy benefit managers arose to fulfill a need created by the Medicare Modernization Act. But now these companies are contributing to escalating drug prices, the very opposite of their original purpose.

The SEC has allowed pharma CEOS to block shareholder resolutions that seek detail on price increases for major medicines.

Without laws to enforce them, the president's ideas to control drug prices will do just the opposite.

Trump told pharmaceutical executives the government was paying "astronomical" prices for medicines in its health programs for older, disabled and poor people and said he would soon appoint a new U.S. Food and Drug Administration leader.

After his promise to bring down drug spending, the ARCA pharmaceutical index fell 2 percent.

Takeda CFO James Kehoe said the company was on the hunt for hit drugs.

Critics say the 21st Century Cures Act would permanently weaken the Food and Drug Administration.